ArticleMicrobiology spectrum2026
Validation of sample pooling for high-throughput RT-qPCR subtyping of avian influenza A(H5).
Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Highly pathogenic avian influenza A(H5N1) is a global health threat due to its high historical virulence and increasing mammalian host range, as demonstrated by the 2024-2025 outbreak among U.S. dairy cattle, with 71 confirmed human infections. While human-to-human transmission has not yet been documented, limited pre-existing human immunity, and uncertainty about evolutionary barriers to human infection make H5N1 a potential pandemic threat. Expanding testing capacity for H5N1 beyond its currently limited scope would be critical for response to potential outbreaks. Thus, we developed and validated a dual-target reverse transcription PCR assay for H5 subtyping of pooled influenza A-positive samples. The assay targets two regions of the hemagglutinin (HA) gene of influenza A(H5). Using contrived samples containing inactivated bovine H5N1 virus, we determined the assay's 95% lower limit of detection for individual samples (58 copies/mL; 95% confidence interval [CI]: 50 to 66 copies/mL) and eight-sample pools (2,465 copies/mL; 95% CI: 1,969 to 3,756 copies/mL). The assay demonstrated 100% positive percent agreement, detecting H5 in all contrived H5-positive pools (32/32 pools; 95% CI: 89.1% to 100.0%) where the contrived positive samples ranged from 500,000 to 3,906 copies/mL. We observed 100% negative percent agreement in H5-negative, influenza A-positive pools (32/32; 95% CI: 89.1% to 100.0%). Though sample pooling reduced analytical sensitivity, contrived samples with H5 virus present at levels typically found in human respiratory infections were detected in eight-sample pools. This approach has the potential to increase testing capacity for influenza A (H5) while maintaining adequate sensitivity, enhancing preparedness for potential outbreaks.IMPORTANCEAvian influenza A(H5N1) poses a potential pandemic threat. H5N1 testing capacity is currently limited. We validated an influenza A (H5) subtyping RT-qPCR for testing pooled samples to increase capacity. The assay displays adequate analytical sensitivity to detect clinical respiratory infections based on prior human cases. This proactive assay validation enhances outbreak preparedness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.